Nutritional Outlook recently interviewed Shawn Baier, Vice President of Business Development for TSI Group SupplySide East, to discuss opportunities in weight management and energy sectors.

Baier highlighted the growing interest in GLP-1 receptor agonists such as Ozempic and underscored the importance for ingredient and supplement companies to address the challenges associated with their use.

According to Baier, GLP-1 RA usage often severely restricts nutritional intake, verging on starvation. Baier emphasized the need for users to prioritize nutrient-dense, low-calorie foods to obtain essential macronutrients and micronutrients.

“We know the whole concept of yo-yo dieting. When people stop using the drug and they go off it and what happens, they get this rebound. It’s very well documented in literature that there’s a gain back. Well, they don’t gain back that same percentage of muscle lost and fat regain. They gain mostly fat back,” Baier says.

Additionally, Baier discussed the issue of unwanted muscle loss during drug use and cited studies showing that supplementation with myHMB® during weight loss can help preserve muscle mass.

For the full interview with Shawn Baier, please click here.